Kinled Holding

Kinled Holding

Kinled Holding traces to 1924 and the Aisher family’s Marley roof-tile business in the United Kingdom. Patrick Aisher, the current chairman and family scion, directs the firm from Hong Kong. The family has moved from industrial manufacturing into a global investment program focused on technology commercialization. The firm allocates across life sciences, fintech and digital technology. Life sciences account for more than half the book and include medical devices, robotics, neuromodulation and drug discovery. Digital technology and fintech each represent roughly one-quarter and target SaaS networks, embedded payments and insurance platforms. Kinled commits to ten independently managed funds—four life-science vehicles in Vienna and Zurich (€300M AUM) and six digital-technology vehicles in Vienna, Zurich, London, Prague, Bratislava and Helsinki (€225M AUM). It also executes direct co-investments and SPVs alongside Concentric and Speedinvest. Positions span Europe, North America and Asia-Pacific, with 16 companies in the United States alone. The firm employs executives across Hong Kong, Switzerland and Austria and maintains a network of incubators and accelerators. It seeded CEBINA at the University of Vienna, Mountain Labs and Danube BioVentures. Kinled reports seeing more than 2,000 plans annually and completing deep diligence on 150 before investing in two to four companies. No operational events from the last 24 months appear in public records. Kinled structures investments through three venture accelerators and two EU-regulated funds that it founded and manages, plus a special-opportunity vehicle that co-invests with Swiss, EU, US and UK technology funds. This architecture lets the firm originate deals from university laboratories, retain governance influence and recycle capital without external limited-partner pressure.